A. Clamp, Catharine Porter, Ann White, Alys Irving, Angela Casbard, Marcia Hall, G. Eminowicz, Angela George, Axel Walther, Adrian Franklin, Azmat Sadozye, Louise Hanna, Andrew Hughes, Rene Roux, Rosemary Lord, Rebecca Bowen, Joey Wood, Clara Sentamans, Rebecca Kristeleit, G. Jayson
{"title":"407 COPELIA:复发性子宫内膜癌每周紫杉醇联合或不联合西地尼布或奥拉帕利联合西地尼布的三臂随机II期试验","authors":"A. Clamp, Catharine Porter, Ann White, Alys Irving, Angela Casbard, Marcia Hall, G. Eminowicz, Angela George, Axel Walther, Adrian Franklin, Azmat Sadozye, Louise Hanna, Andrew Hughes, Rene Roux, Rosemary Lord, Rebecca Bowen, Joey Wood, Clara Sentamans, Rebecca Kristeleit, G. Jayson","doi":"10.1136/ijgc-2024-esgo.24","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"256 15","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"407 COPELIA: a 3-arm randomised phase II trial of weekly paclitaxel with or without cediranib or olaparib with cediranib in recurrent endometrial cancer\",\"authors\":\"A. Clamp, Catharine Porter, Ann White, Alys Irving, Angela Casbard, Marcia Hall, G. Eminowicz, Angela George, Axel Walther, Adrian Franklin, Azmat Sadozye, Louise Hanna, Andrew Hughes, Rene Roux, Rosemary Lord, Rebecca Bowen, Joey Wood, Clara Sentamans, Rebecca Kristeleit, G. Jayson\",\"doi\":\"10.1136/ijgc-2024-esgo.24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"256 15\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
407 COPELIA: a 3-arm randomised phase II trial of weekly paclitaxel with or without cediranib or olaparib with cediranib in recurrent endometrial cancer